Genetic or pharmacological inhibition of PDE9A improved cardiac function in pressure overload mice undergoing transverse aortic constriction [31], suggesting that PDE9A inhibition is a new potential target for HF therapy. This evidence concerns the gene PDE9A and hydrops fetalis.